Ceva Santé Animale (“Ceva”), the #5 animal health company present in 47 countries worldwide, and Deepflare sp. z o.o. (“Deepflare”) specializing in machine learning solutions for vaccine and immunotherapy development, announce an partnership to advance AI-driven vaccine discovery.
This partnership leverages Deepflare's AI capabilities and Ceva's extensive expertise in animal health, to design breakthrough next-generation vaccines, unlocking market opportunities for both companies and the entire animal health industry (worth over $10 billion according to Fortune Business Insights).
With Deepflares’ expertise in immunopeptidomic data acquisition and processing, the collaboration will allow for the efficient identification of the most promising antigen candidates. This will significantly improve the vaccine development processes.
Piotr Grzegorczyk, CEO of Deepflare shared: “The partnership with Ceva marks a significant milestone for Deepflare, enabling us to gain invaluable insights into the vaccine discovery and contribute to the development of life-saving products by the global leader in the field.”
Thomas Lewiner, Ceva’s Chief Bioinformatics Officer said “This cooperation reinforces our commitment to innovation in the field of vaccine technologies and has the potential to greatly enhance our core R&D activities. We are looking forward to working together with Deepflare in order to achieve our One Health mission.“
